Focused on oncology, WILEX develops diagnostic and therapeutic product candidates based on antibodies, which are available for out-licensing. The subsidiary Heidelberg Pharma GmbH offers preclinical contract research services and an antibody drug conjugate (ADC) technology platform.


Latest News

30.03.2017: Press release: WILEX announces financial figures for fiscal year 2016 and provides business update. WILEX AG today published its financial results and annual report for the fiscal year 2016 (1 December 2015 – 30 November 2016) and its outlook for 2017.....More





Seite gelesen: 49689 | Heute: 1981